[Federal Register Volume 77, Number 54 (Tuesday, March 20, 2012)]
[Notices]
[Pages 16239-16244]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-6707]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0389]
Medical Device User Fee Act; Public Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing a public
meeting to discuss proposed recommendations for the reauthorization of
the Medical Device User Fee Act (MDUFA) for fiscal years (FYs) 2013
through 2017. MDUFA authorizes FDA to collect user fees and use them
for the process for the review of medical device applications. The
current legislative authority for MDUFA expires on October 1, 2012. New
legislation will be required for FDA to collect medical device user
fees for future FYs. Following discussions with the device industry and
periodic consultations with public stakeholders, the Federal Food,
Drug, and Cosmetic Act (FD&C Act) directs FDA to publish the
recommendations for the reauthorized program in the Federal Register,
hold a meeting at which the public may present its views on such
recommendations, and provide for a period of 30 days for the public to
provide written comments on such recommendations. FDA will then
consider such public views and comments and revise such recommendations
as necessary.
DATES: The public meeting will be held on March 28, 2012 from 9 a.m. to
5 p.m. Registration to attend the meeting must be received by March 26,
2012. Submit either electronic or written comments by April 16, 2012.
Location: The meeting will be held at the Hubert H. Humphrey
Building, 200 Independence Avenue SW., Washington, DC 20201. For
directions and metro information please visit the following Web site:
http://www.hhs.gov/about/hhhmap.html. The public meeting will also be
available to be viewed online via webcast. Registration is required to
view the webcast.
Contact Person: Cindy Garris, Center for Devices and Radiological
Health, Food and Drug Administration, 10903 New Hampshire Ave. Bldg.
66, Rm. 4459, Silver Spring, MD 20993, 301-796-5861, FAX: 301-847-8142,
email: [email protected].
Registration and Oral Presentations: If you wish to attend and/or
speak at the meeting or view the webcast, please register by March 26,
2012. To register for the meeting, please visit http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm (or go to
the FDA Medical Devices News & Events--Workshops & Conferences calendar
and select this public meeting from the posted events list). Please
provide complete contact information for each attendee, including name,
title, affiliation, address, email address, and phone number.
Registrants wishing to speak during the open comment period should note
that when registering. We
[[Page 16240]]
will try to accommodate all persons who wish to speak. The time
allotted for an individual to speak may depend on the number of persons
who wish to speak. Registration is free and will be on a first-come,
first-served basis, with the following exception. Early registration is
recommended because seating is limited. FDA may limit the number of
participants from each organization based on space limitations.
Registrants will receive confirmation once they have been accepted.
Onsite registration on the day of the meeting will not be available.
If you need special accommodations due to a disability, please
contact Cindy Garris (email: [email protected] or 301-
796-5861) at least 2 days before the meeting.
Comments: FDA is holding this public meeting to hear stakeholders'
views on the draft recommendations for the reauthorized user fee
program (MDUFA III), including suggestions for any changes that FDA
should consider. FDA policy issues are beyond the scope of the user fee
program. Accordingly, the public comments should focus on MDUFA III
draft recommendations.
Regardless of attendance at the public meeting, interested persons
may submit written comments to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov. All comments should be identified with the docket
number found in brackets in the heading of this document. It is no
longer necessary to send two copies of mailed comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
SUPPLEMENTARY INFORMATION:
I. Introduction
FDA is announcing its intention to hold a public meeting to discuss
proposed recommendations for the reauthorization of the Medical Device
User Fee Amendments of 2007 (MDUFA), which authorizes FDA to collect
user fees and use them for the process for the review of device
applications until October 1, 2012. Without new legislation, FDA will
no longer be able to collect user fees for future fiscal years to fund
the medical device review process.
As required by section 738A(b)(2), (3), and (6) of the FD&C Act (21
U.S.C. 379j-1(b)(2), (3), and (6)), FDA obtained prior public input and
negotiated an agreement with regulated industry while periodically
consulting with patient and consumer advocacy groups and making minutes
of negotiation and stakeholder meetings publicly available (Ref. 1).
Section 738A(b)(4) of the FD&C Act , requires that, after holding
negotiations with regulated industry and before transmitting the
Agency's final recommendations to Congress for the reauthorized program
(MDUFA III), we do the following: (1) Present the draft recommendations
to the Committee on Energy and Commerce of the U.S. House of
Representatives and the Committee on Health, Education, Labor, and
Pensions of the U.S. Senate; (2) publish the draft recommendations in
the Federal Register; (3) provide a period of 30 days for the public to
provide written comments on the draft recommendations; (4) hold a
meeting at which the public may present its views on the draft
recommendations; and (5) after consideration of public views and
comments, revise the draft recommendations as necessary. This notice,
the 30 day comment period, and the public meeting will satisfy certain
of these requirements. After the public meeting, we will revise the
draft recommendations as necessary. In addition, the Agency will
present the draft recommendations to the Congressional committees.
The purpose of the meeting is for the public to present its views
on the draft recommendations for the reauthorized program (MDUFA III).
In general, the meeting format will include a brief presentation by
FDA, but will focus on hearing from different stakeholder interest
groups (such as patient advocates, consumer advocates, industry, health
professionals, and academic researchers). The Agency will also provide
an opportunity for individuals to make presentations at the meeting and
for organizations and individuals to submit written comments to the
docket before and after the meeting. The following information is
provided to help potential meeting participants better understand the
history and evolution of the medical device user fee program and the
current status of the MDUFA III draft recommendations.
II. What is the medical device user fee program? What does it do?
In the years preceding enactment of Medical Device User Fee and
Modernization Act of 2002 (MDUFMA) (Pub. L. 107-250), FDA's medical
device program suffered a long-term, significant loss of resources that
undermined the program's capacity and performance. MDUFMA was enacted
``in order to provide the Food and Drug Administration (FDA) with the
resources necessary to better review medical devices, to enact needed
regulatory reforms so that medical device manufacturers can bring their
safe and effective devices to the American people at an earlier time,
and to ensure that reprocessed medical devices are as safe and
effective as original devices'' (H.R. Rep. No. 107-728, at 21 (2002)).
MDUFMA had a 5-year time frame and contained two particularly important
features which relate to reauthorization:
User fees for the review of medical device premarket
applications, reports, supplements, and premarket notification
submissions provided additional resources to make FDA reviews more
timely, predictable, and transparent to applicants. MDUFMA fees and
increased appropriations for the medical device program helped FDA
expand available expertise, modernized its information management
systems, provided new review options, and provided more guidance to
prospective applicants. The ultimate goal was for FDA to approve and
clear safe and effective medical devices more rapidly, benefiting
applicants, the health care community and, most importantly, patients.
Negotiated performance goals for many types of premarket
reviews provided FDA with benchmarks for measuring review improvements.
These quantifiable goals became more demanding each year and included
FDA decision goals and cycle goals (cycle goals refer to FDA actions
prior to a final action on a submission). Under MDUFMA, FDA also agreed
to several commitments that did not have specific time frames or direct
measures of performance, such as expanding the use of meetings with
industry, maintenance of current performance in review areas where
specific performance goals had not been identified, and publication of
additional guidance documents.
Medical device user fees and increased appropriations were
essential to support high-quality, timely medical device reviews, and
other activities critical to the device review program.
MDUFMA provided for fee discounts and waivers for small businesses.
Small businesses make up a large proportion of the device industry, and
these discounts and waivers helped reduce the financial impact of the
user fees on this sector of the device industry, which plays an
important role in fostering innovation.
FDA provided periodic reports on its progress towards meeting these
performance goals and commitments to stakeholders and Congress. FDA
also
[[Page 16241]]
provided an annual financial report to Congress, which provided
transparency and accountability regarding the Agency's use of the
additional resources provided by MDUFMA. Although FDA made progress
towards achieving MDUFMA's central objectives, progress was limited by
financial shortfalls and unpredictable fee revenues caused by
variability in pre-market submission quantities.
In August 2005, Congress enacted the Medical Device User Fee
Stabilization Act (Pub. L. 109-45) (MDUFSA), which modified several
provisions of MDUFMA. MDUFSA: (1) Repealed the appropriations trigger
for FY 2003 and FY 2004 and allowed for tolerances of up to 1 percent
of the appropriations trigger for FY 2005-2007; (2) provided for
predictable application fees by establishing fixed annual fees for FY
2006 and FY 2007, although at a lower rate of increase than under the
original legislation; and (3) expanded the definition of ``small
business'' for FY 2006 and FY 2007. However, MDUFSA did not address the
issue of ensuring predictable revenues for FDA.
In 2007, Congress reauthorized medical device user fees through FY
2012 under the Medical Device User Fee Amendments of 2007 (MDUFA II)
(title II of the Food and Drug Administration Amendments Act of
2007(FDAAA) (Pub. L. 110-85).
Under MDUFA II, the user fee program remained intact, with a few
significant modifications to the program. The user fee framework was
changed to provide a more reliable and stable funding stream.
Specifically, MDUFA II included establishment registration as a new fee
type that provided a more predictable amount of funds to be collected
by the Agency in any given year. MDUFA II also included changes to the
performance goals. Compared to MDUFMA, there were fewer performance
goals under MDUFA II, yet the goals were more demanding. FDA published
the commitment letter outlining the goals in the last reauthorization,
as well as a number of reports that provide the public with useful
background on MDUFMA, FDAAA, and MDUFA II (Ref. 2). FDA also posted
video presentations on the medical device user fee program to give the
public more background information on the program (Ref. 3).
III. Proposed MDUFA III Recommendations
In preparing the proposed recommendations to transmit to Congress
for MDUFA reauthorization, we have conducted discussions with the
device industry, and we have consulted with stakeholders as required by
law. We began the MDUFA reauthorization process with a public meeting
held on September 14, 2010 (75 FR 49502, August 13, 2010). The meeting
included presentations by FDA and a series of panels representing
different stakeholder groups, including patient advocates, consumer
groups, the device industry, health care professionals, and scientific
and academic experts.
From January 2011 through February 2012, FDA conducted negotiations
with representatives of the device industry: The Advanced Medical
Technology Association (AdvaMed); the Medical Device Manufacturers
Association (MDMA); the Medical Imaging and Technology Alliance (MITA);
and, the American Clinical Laboratory Association (ACLA). FDA also held
monthly consultations with public stakeholders during that time period.
As directed by Congress, FDA posted minutes of these discussions on its
Web site (Ref. 4).
The proposed recommendations for MDUFA III address many of the
priorities and concerns identified by public stakeholders and the
device industry, and many of the important challenges identified by
FDA. Each recommendation is briefly described with reference to the
applicable section of the draft commitment letter (Ref. 5).
In conjunction with the proposed enhancements and performance goals
outlined in the draft commitment letter, FDA is proposing new user fees
and several statutory changes. The specific proposals are briefly
described with reference to the applicable section of the draft
legislative language (Ref. 6).
A. Process Improvements
FDA is proposing several process improvements designed to increase
the consistency, predictability, transparency, and efficiency of the
device review program.
1. Pre-Submissions
A Pre-Submission provides the opportunity for an applicant to
obtain FDA feedback prior to submission of an investigational device
exemption or marketing application. Although no specific resources are
being allocated through the proposed MDUFA III user fees for the Pre-
Submission program, FDA is proposing that we will institute a
structured process for managing Pre-Submissions, as resources permit,
and not to the detriment of meeting the quantitative review timelines
in this proposal and statutory obligations. FDA is proposing to issue a
draft guidance document and final guidance document on Pre-Submissions.
The draft commitment letter includes additional details on the manner
in which FDA intends to manage Pre-Submissions. These details can be
found in section I.A of the draft commitment letter.
2. Submission Acceptance Criteria
FDA is proposing to implement revised submission acceptance
criteria through the publication of guidance. These revised criteria
are intended to ensure that FDA is only reviewing complete submissions.
The guidance will outline electronic copy of submissions (e-Copy) and
objective criteria for revised ``refuse to accept/refuse to file''
checklists. This recommendation can be found in section I.B of the
draft commitment letter. FDA is also proposing corresponding statutory
language mandating e-Copy of submissions; this statutory requirement
would be implemented through the guidance described in this paragraph.
(See section III.L of this document for further information about this
proposed statutory change).
3. Interactive Review
FDA is proposing to continue to incorporate an interactive review
process to provide for, and encourage, informal communication between
FDA and applicants to facilitate timely completion of the review
process based on accurate and complete information. This recommendation
can be found in section I.C of the draft commitment letter.
4. Guidance Document Development
FDA is proposing to apply user fee revenues to supplement the
improvement of the process of developing, reviewing, tracking, issuing,
and updating guidance documents. This recommendation can be found in
section I.D of the draft commitment letter.
5. Third Party Review
Although no specific resources are being allocated through the
proposed MDUFA III user fees for the Third Party Review program, FDA is
recommending reauthorization of the program and will work with
interested parties to strengthen and improve the current program as
resources permit. This recommendation can be found in section I.E of
the draft commitment letter.
6. Patient Safety and Risk Tolerance
FDA proposes to fully implement final guidance on factors to
consider when making benefit-risk determinations in medical device
[[Page 16242]]
premarket review. FDA also proposes to meet with patient groups during
MDUFA III to better understand the patient perspective on disease
severity or unmet medical need. FDA also proposes to increase its
utilization of FDA's Patient Representatives to provide patients' views
early in the medical product development process. This recommendation
can be found in section I.F of the draft commitment letter.
7. Low Risk Medical Device Exemptions
FDA proposes to identify additional low risk medical devices to
exempt from premarket notification. This recommendation can be found in
section I.G of the draft commitment letter.
8. Emerging Diagnostics
FDA proposes to work with industry to develop a transitional In
Vitro Diagnostics (IVD) approach for the regulation of emerging
diagnostics. This recommendation can be found in section I.H of the
draft commitment letter.
B. Review Performance Goals--Fiscal Years 2013 Through 2017 as Applied
to Receipt Cohorts
FDA is proposing to meet more rigorous goals for MDUFA III while
streamlining management of the program. In making these proposals, we
have taken into account efficiencies planned for in MDUFA III
including: Additional scientific, regulatory, and leadership training;
additional staff, including those with expertise demanded by
increasingly complex device reviews; improved submission acceptance
criteria; and information technology improvements that allow us to
better track and manage the device review process.
FDA is proposing to eliminate the ``two-tier'' goal structure that
we believe is an impediment to improving average total time to decision
and to reaching the ultimate goal of the medical device user fee
program--for safe and effective devices to reach patients and health
care professionals more quickly. FDA is proposing a more simplified
goal structure, which will be easier to implement and will improve
predictability of the program, leaving the program less prone to
unintended consequences. The simplified goal structure includes a
single, high percentage goal for each performance metric. This provides
more clarity to industry so applicants will know when to expect
feedback from the Agency on their marketing submissions, and allows the
Agency's review staff to better manage their time. This structure also
allows more flexibility in the Agency's management strategy, allowing
for adjustments as needed to ensure achievement of the desired
outcomes--specifically, reducing review cycles and reducing average
total time to decision.
FDA is proposing decision goals of 180 FDA days for premarket
approval applications (PMAs) that do not require Advisory Committee
input and for 180-Day PMA Supplements, 320 FDA days for PMAs that do
require Advisory Committee input, 90 FDA days for Real-Time PMA
Supplements, and 90 FDA days for premarket notification (510(k))
submissions. FDA is proposing performance goals for Clinical Laboratory
Improvement Amendments (CLIA) waiver applications: 210 FDA days for
dual submission of a 510(k) and CLIA waiver application; 180 FDA days
for a CLIA waiver application not requiring Advisory Committee input;
and 330 FDA days for CLIA waiver applications that do require Advisory
Committee input. For each of these decision goals, FDA is proposing to
``ramp-up'' the percentage of applications that will be completed
within the goal time line during the 5-year time period to correspond
with the timetable for additional staff to be hired during MDUFA III.
The goal percentages will increase to 90 or 95 percent in the final
years of the program, depending on the submission type. Additionally,
FDA is proposing to institute an acceptance/filing communication and
Substantive Interaction goal for several submission types, which will
track the Agency's communication with the applicant at specified points
during the review process. FDA is proposing to retain the existing
goals for Biological Licensing Applications (BLAs) and their
supplements. Additional details regarding all of the quantitative
review performance goals can be found in section II of the draft
commitment letter.
C. Shared Outcome Goals
FDA and representatives of the device industry believe that the
process improvements outlined in the draft commitment letter, when
implemented by all parties as intended, should reduce the average Total
Time to Decision for PMA applications and 510(k) submissions, provided
that the total funding of the device review program adheres to the
assumptions underlying the agreement. Reducing average total time to
decision is an important aspect of the ultimate goal of the user fee
program, so that safe and effective devices reach patients and health
care professionals more quickly. FDA proposes to report, on an annual
basis, the average Total Time to Decision, as defined in the draft
commitment letter, for PMA and 510(k) submissions, with shared goals
for FDA and industry of 395 calendar days for PMAs and 135 calendar
days for 510(k)s beginning with the FY 2013 receipt cohort, declining
to 385 calendar days for PMAs and 124 calendar days for 510(k)s for the
FY 2017 receipt cohort. Additional details regarding the shared outcome
goals can be found in section III of the draft commitment letter.
D. Infrastructure
FDA is proposing to apply user fee revenues to improve scientific
and regulatory review capacity by reducing the ratio of review staff to
front line supervisors and enhancing and supplementing scientific
review capacity. FDA is seeking to obtain streamlined hiring authority
in order to accomplish this (see section III.M of this document). FDA
is proposing to apply user fee revenues to supplement training
programs. FDA is proposing to continue efforts to improve its IT
systems. Additional details regarding the infrastructure proposals can
be found in section IV of the draft commitment letter.
E. Independent Assessment of Review Process Management
In order to implement continued program improvements and
efficiencies, FDA is proposing to conduct a comprehensive assessment of
the process for the review of device applications. FDA is proposing to
incorporate findings and recommendations of the independent assessment
into its management of the premarket review program. Additional details
regarding the independent assessment proposal can be found in section V
of the draft commitment letter.
F. Performance Reports
FDA is proposing to report its progress toward meeting the goals in
the draft commitment letter through quarterly and annual reporting. The
proposed reporting structure includes more detailed reporting than the
Agency agreed to provide during MDUFA II. Additional details regarding
the performance reporting structure can be found in section VI of the
draft commitment letter.
G. MDUFA III Inflation and Fee Adjustments
In calculating user fees for each new FY in MDUFA III, FDA proposes
to adjust the base revenue amount by inflation. This methodology is
specified in the draft legislative language. The
[[Page 16243]]
inflation adjuster accounts for changes in FDA's costs related to
payroll compensation and benefits as well as changes in non-payroll
costs through use of the Consumer Price Index. This weighted composite
inflation adjuster will provide a degree of assurance that fees during
MDUFA III keep pace with FDA's costs. Additionally, FDA proposes to
adjust establishment registration fees annually, as needed, to account
for any unanticipated variations in submission and registration
quantities that are likely to result in FDA collecting more or less
than the authorized amount of fees each year (as adjusted for
inflation). Additional details regarding the annual fee setting and
adjustments can be found in section 738(c) of the draft legislative
language.
H. Impact of MDUFA III Enhancements on User Fee Revenue
Implementing the proposed enhancements discussed in the previous
sections of this document will require approximately $595 million,
before adjustments for inflation, in device user fee revenue over the
course of the 5-year MDUFA III period, FY 2013 through FY 2017.
Proposed user fee collections, before adjustments for inflation, are:
$97,722,301 in FY 2013; $112,580,497 in FY 2014; $125,767,107 in FY
2015; $129,339,949 in FY 2016; and $130,184,348 in FY 2017. This user
fee revenue will support approximately 208 additional full-time
equivalent (FTE) staff by the end of the MDUFA III period. In addition,
these fee levels will support the continued funding of approximately 32
FTEs over current staffing levels that FDA plans to hire by the end of
FY 2012 under MDUFA II using currently authorized and appropriated user
fees. Therefore, the net increase over current staffing levels will be
approximately 240 FTEs as a result of this proposal. Collections
slightly above proposed user fee spending in the early years of MDUFA
III will ensure that funds are available to hire additional staff in
order to meet the proposed commitments, and will be balanced by
collections slightly below proposed user fee spending in the later
years of MDUFA III. As in MDUFA II, the premarket application fee and
the establishment registration fee are set during the annual fee
setting, and other submission fees are determined as a percentage of
the premarket application fee. In MDUFA III, the percentage associated
with a premarket notification (510(k)) is being raised from 1.84
percent of a premarket application fee to 2.0 percent of a premarket
application fee. All other percentages remain the same as during MDUFA
II. Base fee amounts for premarket applications, prior to adjustments
for inflation, are proposed as: $248,000 in FY 2013; $252,960 in FY
2014; $258,019 in FY 2015; $263,180 in FY 2016; and $268,443 in FY
2017. Base fee amounts for establishment registration, prior to annual
adjustments, are proposed as: $2,575 in FY 2013; $3,200 in FY 2014;
$3,750 in FY 2015; $3,872 in FY 2016; and $3,872 in FY 2017. Additional
details regarding the MDUFA III fees can be found in section 738(a) and
(b) of the draft legislative language.
I. Establishment Registration Fee Exemptions
The proposed legislative language eliminates exemptions under MDUFA
II that allowed certain types of establishments to meet their
requirement to register without incurring a fee. This amendment will
increase the base of establishments paying registration fees.
Additional details regarding this modification can be found in section
737(13) of the draft legislative language.
J. Fee Waiver or Reduction Authority
FDA is proposing a provision for the Secretary of Health and Human
Services (Secretary), in the Secretary's sole discretion, to grant a
waiver or reduction of fees if the Secretary finds that such waiver or
reduction is in the interest of public health. Additional details
regarding this provision can be found in section 738(f) of the draft
legislative language.
K. Appropriations and Spending Triggers
FDA is proposing to update the appropriations trigger and the
spending trigger to FY 2009 levels. This will provide assurance to
industry that user fees will be additive to Budget Authority
appropriations, as was the original intent of the user fee program and
of the appropriations and spending triggers. Additional details
regarding these updates can be found in section 738(h)(1)(A) and
(i)(2)(A)(ii) of the draft legislative language.
L. Electronic Copy of Submissions
In order to implement revised submission acceptance criteria, FDA
is proposing statutory language requiring an electronic copy (e-Copy)
to be provided with any pre-submission or submission for devices. The
proposed language provides that implementation of this requirement
would occur following issuance of final guidance providing standards
for such electronic copy. Additional details regarding this provision
can be found under the heading ``Subchapter D--Information and
Education'' in the draft legislative language.
M. Streamlined Hiring Authority
In order to facilitate the steep ramp-up in hiring necessary to
accomplish the goals agreed to in the draft commitment letter, FDA is
proposing statutory language that would grant streamlined hiring
authority to FDA for the first 3 years of MDUFA III. Additional details
regarding this provision can be found under the heading ``STREAMLINED
HIRING AUTHORITY OF THE FOOD AND DRUG ADMINISTRATION TO SUPPORT
ACTIVITIES RELATED TO THE PROCESS FOR THE REVIEW OF DEVICE
APPLICATIONS'' in the draft legislative language.
IV. References
The following references have been placed on display in the
Division of Dockets Management (see Comments) and may be seen by
interested persons between 9 a.m. and 4 p.m., Monday through Friday.
(FDA has verified the Web site addresses, but FDA is not responsible
for any subsequent changes to the Web sites after this document
publishes in the Federal Register.)
1. The minutes from FDA's negotiation and stakeholder meetings are
available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/MedicalDeviceUserFeeandModernizationActMDUFMA/ucm236902.htm.
2. The MDUFA II commitment letter, key Federal Register documents,
MDUFA II-related guidance documents, legislation, performance reports,
and financial reports and plans are available at www.fda.gov/MDUFA.
3. The pre-recorded video presentations are available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/MedicalDeviceUserFeeandModernizationActMDUFMA/ucm109316.htm. FDAAA-
specific information is available at http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/default.htm.
4. The minutes from FDA's negotiation and stakeholder meetings are
available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/MedicalDeviceUserFeeandModernizationActMDUFMA/ucm236902.htm.
5. Further information can be found on FDA's Web site at http://
www.fda.gov/MedicalDevices/NewsEvents/
[[Page 16244]]
WorkshopsConferences/ucm292860.htm.
6. Further information can be found on FDA's Web site at http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm292860.htm.
V. Transcripts
Please be advised that as soon as a transcript is available, it
will be accessible at http://www.regulations.gov and at http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm292860.htm. It may be viewed at the Division of Dockets Management
(see Comments). A transcript will also be available in either hard copy
or on CD-ROM, after submission of a Freedom of Information request.
Written requests are to be sent to the Division of Freedom of
Information (ELEM-1029), Food and Drug Administration, 12420 Parklawn
Dr., Element Bldg., Rockville, MD 20857. Transcripts of the meeting
will be available for review at the Division of Dockets Management and
on the Internet at http://www.regulations.gov approximately 30 days
after the public meeting.
Dated: March 15, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012-6707 Filed 3-15-12; 4:15 pm]
BILLING CODE 4160-01-P